Recent Posts
- MOASC Awards $25,000 Research Grant from AVEO Oncology to Dr. Peter Zang, MD of City of Hope 2025 Cary Presant, MD Investigator Award
- FDA Approves Keytruda / Pembrolizumab for HER2-Positive Gastric Cancer: A Potential New Hope for Patients
- Podcast: Phase III KEYNOTE-921 Trial Insights, Brd7 Loss in Lung Metastasis, CDK4 Selective Inhibition Advances, and Children’s Oncology Group Neuroblastoma Mutation Study
- AACR – Douglas Hanahan, PhD, FAACR, Receives 2025 Pezcoller-AACR Award for Cancer Research Excellence
- Immunotherapy Side Effects Under Scrutiny: New Data on Bone Density and T-Cell Insights
Donate
Oncology Conference Videos
Oncology News
Atezolizumab Stumbles in Triple Negative Breast Cancer Study: SABCS 2024 Results with Charles Geyer
We recognize that That combination also made them immunogenic. And so there was always recognition. Over time we came to appreciate that when you see the immune system in there where there’s immune lymphocytes in the tumor, those tumors, those patients seem to do better even in the absence of drug therapy and with drug therapy they do better still.
FGFR2 Mutations and IDH1 Real-World Data Suggests Caution with Immunotherapy in Specific mBTC – ASCO GI Dr. Richard Kim, MD Moffitt Cancer Center
In the rapidly evolving field of cancer treatment, the application of comprehensive genomic profiling (CGP)…
EMBER-3 Trial: Pioneering Results in Advanced Breast Cancer TreatmentThe results of the Phase 3 EMBER-3…
BRCA Carriers Slicing Breast Cancer Odds: Does Surgery Really Lead to Longevity Leaps? Text: @OncoAlert…
Why isn’t CAR-T Therapy Revolutionizing the Fight Against GI Cancers? 17 Trial Insights from ASCO GI 2025
Introduction:Recent data from the American Society of Clinical Oncology (ASCO) GI Cancers Symposium 2025, as…
Short-Interval ctDNA Testing Rapid Monitoring of Tumor Response in GI Cancer – Sakti Chakrabarti, MD ASCO GI
Abstract: Circulating tumor DNA (ctDNA) has a short half-life (<2 hours) which may permit real-time…
SABCS 2024
What is the new treatment for non-small cell lung cancer? Changes in the Perioperative Setting [54 Slides] Karen Reckamp, MD
…At the MOASC Annual Oncology Summit & Research Symposium, Dr. Karen Reckamp, MD, MS, a…